Month: May 2022

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal adhesions CARLSBAD, Calif., May 13, 2022 (GLOBE NEWSWIRE) — Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported its financial results for the quarter ended March 31, 2022. Additionally, the Company provided a clinical program update for its lead asset in development, LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Recent HighlightsExtended cash runway with a $2.0 million registered direct offering. Received...

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) — There was an error at the end of the first paragraph. March 31, 2021 has been changed to March 31, 2022. There were no other changes to the release. Please find full corrected release below. ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2022. “In Q1 of 2022 we have continued the significant progress of late 2021, advancing and expanding our portfolio of differentiated therapeutic product candidates in diseases such as Alzheimer’s...

POINT’s manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. CTA filed with Health Canada for Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) targeted program. Trial is expected to commence this summer. INDIANAPOLIS, May 13, 2022 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the first quarter ended March 31, 2022 and provided a business update. “There were two very significant milestones for POINT in the first quarter of 2022,” said Dr. Joe McCann, CEO...

MAURITIUS, May 13, 2022 (GLOBE NEWSWIRE) — Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX)( “Alphamin” or the “Company”), a producer of 4% of the world’s mined tin1 from its high grade operation in the Democratic Republic of Congo, is pleased to provide the following operational update for the quarter ended March 2022:Q1 EBITDA2 of US$98.1m, up 32% from prior quarter Contained tin sold up 9% from the prior quarter to 3,336 tonnes Record plant recovery of 78% achieved (previous quarter: 75%) Net cash2 position increased 90% to US$129.8m, after a US$30m dividend payment Maiden mineral resource declared and subsequently updated at Mpama South Decision to commence construction of the Mpama South mine following positive PEA results Continued high grade assay results from ongoing drilling campaigns at Mpama North and Mpama SouthOperational...

Iceland Seafood will publish its Interim Financial Statement for Q1 2022 after closing of markets on May 17th 2022. The same day at 4.15pm, the company will host a meeting for investors and market participants, where management will present and discuss the results. The meeting will be held at the company‘s premises at Köllunarklettsvegur 2, 104 Reykjavík. The meeting will also be webcasted live in Icelandic, a link to the webcast and investor presentation will be provided before the meeting commence.  Participants to the online meeting can send questions in writing prior and during the meeting to the email investors@icelandseafood.com.

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to be announced in June 2022Advancing ONS-5010 toward potential marketing approval in early 2023U.S. pre-launch commercial planning continues to ramp upOperations supported by access to funding expected to be sufficient to launch LYTENAVA, if approvedISELIN, N.J., May 13, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2022. Recent Corporate HighlightsSuccessfully submitted a BLA...